Dogwood Therapeutics, Inc. (DWTX): R&D Expense
$21.87M
Year ended 2025-12-31
$22.78M
Trailing 12 months to 2026-06-30
+39.4%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.87M | +519.3% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $3.53M | +104.3% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $1.73M | -78.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $8.07M | -25.3% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $10.80M | n/m | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | $194.0K | n/a | 2022-03-18, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | $21.87M | +519.3% |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $17.86M | +54.7% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $73.70M | +25.4% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $7.76M | +138.6% |
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $26.88M | -41.8% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $21.33M | +32.7% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $25.24M | -53.3% |
Compare DWTX, VTVT, STTK, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗